Complete financial analysis of Alpha Tau Medical Ltd. (DRTS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alpha Tau Medical Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shandong Kuntai New Material Technology Co., Ltd. (001260.SZ) Income Statement Analysis – Financial Results
- Paragon ID SA (PID.PA) Income Statement Analysis – Financial Results
- Fangda Special Steel Technology Co., Ltd. (600507.SS) Income Statement Analysis – Financial Results
- Pilgrim’s Pride Corporation (PPC) Income Statement Analysis – Financial Results
- P2 Gold Inc. (PGLDF) Income Statement Analysis – Financial Results
Alpha Tau Medical Ltd. (DRTS)
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.07M | 979.00K | 776.00K | 86.00K | 0.00 |
| Gross Profit | -1.07M | -979.00K | -776.00K | -86.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 26.42M | 20.89M | 11.45M | 7.54M | 6.64M |
| General & Administrative | 7.33M | 10.27M | 1.86M | 1.41M | 977.00K |
| Selling & Marketing | 1.92M | 974.00K | 482.00K | 288.00K | 397.00K |
| SG&A | 9.26M | 11.25M | 2.34M | 1.70M | 1.37M |
| Other Expenses | -72.20M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -35.68M | 32.14M | 13.79M | 9.24M | 8.01M |
| Cost & Expenses | -35.68M | 32.14M | 13.79M | 9.24M | 8.01M |
| Interest Income | 4.76M | 1.79M | 211.00K | 613.00K | 776.00K |
| Interest Expense | 39.00K | 1.77M | 13.27M | 217.00K | 0.00 |
| Depreciation & Amortization | 1.07M | 979.00K | 776.00K | 86.00K | 66.00K |
| EBITDA | -28.03M | -32.74M | -13.22M | -9.16M | -7.94M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 35.68M | -32.14M | -13.79M | -9.24M | -8.01M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -64.82M | -1.61M | -13.47M | 520.00K | -308.00K |
| Income Before Tax | -29.14M | -33.74M | -27.26M | -8.72M | -8.32M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 16.00K | 20.00K | 7.00K | 158.00K | 146.00K |
| Net Income | -29.16M | -33.76M | -27.27M | -8.88M | -8.46M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.42 | -0.53 | -0.67 | -0.22 | -0.13 |
| EPS Diluted | -0.42 | -0.53 | -0.67 | -0.22 | -0.13 |
| Weighted Avg Shares Out | 69.38M | 63.53M | 40.53M | 40.43M | 67.62M |
| Weighted Avg Shares Out (Dil) | 69.38M | 63.53M | 40.53M | 40.43M | 67.62M |
Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium
JERUSALEM, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the Ladenburg...
Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference
JERUSALEM, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the Citi...
Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
JERUSALEM, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-emitters cancer therapy Alpha DaRT®, announced today that it has been accepted into the prestigious Total...
Alpha Tau Treats First Patient with Recurrent Lung Cancer
JERUSALEM, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that its first patient with recurrent lung cancer has...
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
-Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this patient population - -Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of...
Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference
JERUSALEM, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present a corporate overview...
Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- First patient treated in May for liver metastases from colorectal cancer - - Publication in June in Cancers journal of long-term safety and efficacy data in multiple hard-to -treat superficial cancers , with an overall response rate of almost...
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
The pooled analysis included data from 4 i nternational clinical trials spanning a n array of hard-to-treat indications including skin, head & neck, and oral cavity.
Alpha Tau to Present at the Jefferies Global Healthcare Conference
JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview...
Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow -
Source: https://incomestatements.info
Category: Stock Reports